Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a)
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
ConclusionsPelacarsen did not result in a lower risk of major adverse cardiovascular events than placebo at a median follow-up of 4.7 years.
Appeared: Monday, November 9. New England Journal of Medicine. Peer-reviewed journal.